Acknowledgment I thank Dr Brian Turpin for editorial input Annotated References Cardinale D, Colombo A, Bacchiani G, et al Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy Circulation.2015;131(22):1981–1988 Study in adult patients with cancer demonstrating that early detection and initiation of therapy, during cancer treatment, portends improved cardiac outcomes Chow EJ, Asselin BL, Schwartz CL, et al Late mortality after dexrazoxane treatment: a report from the Children's oncology group J Clin Oncol.2015;33(24):2639–2645 Analysis using the CCSS demonstrating that dexrazoxane does not have a negative effect on late mortality in a group of pediatric cancer of mixed etiology Chow EJ, Chen Y, Kremer LC, et al Individual prediction of heart failure among childhood cancer survivors J Clin Oncol.2015;33(5):394– 402 Follow-up report to Mulrooney et al (2009) work with the CCSS, using patient and treatment risk factors to make a prediction model for development of CTC in survivors This work serves as the basis for the risk calculator www.ccss.stjude.org/chfcalc Lipshultz SE, Adams MJ, Colan SD, et al Longterm cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American heart association Circulation.2013;128(17):1927–1995 Comprehensive review of pediatric issues pertaining to cardiovascular outcomes in pediatric oncology, including detailed analysis of the important papers in the field and state-ofthe-art management considerations Currently the definitive work in pediatric cardio-oncology Lipshultz SE, Rifai N, Dalton VM, et al The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia N Engl J Med.2004;351(2):145–153 Seminal work determining the cardioprotective effect of dexrazoxane in patients undergoing treatment with doxorubicin The focus of the study was a pediatric population Mulrooney DA, Yeazel MW, Kawashima T, et al Cardiac outcomes in a cohort of adult survivors ... the American heart association Circulation.2013;128(17):1927–1995 Comprehensive review of pediatric issues pertaining to cardiovascular outcomes in pediatric oncology, including detailed analysis of the important papers in the field and state-ofthe-art management considerations... Analysis using the CCSS demonstrating that dexrazoxane does not have a negative effect on late mortality in a group of pediatric cancer of mixed etiology Chow EJ, Chen Y, Kremer LC, et al Individual prediction of heart failure among childhood... of the important papers in the field and state-ofthe-art management considerations Currently the definitive work in pediatric cardio-oncology Lipshultz SE, Rifai N, Dalton VM, et al The effect of dexrazoxane on myocardial injury in